Case Report: Adjunctive Oxycodone for the Treatment of Refractory Bipolar Depression
J Clin Psychiatry 2012;73(7):992
© Copyright 2017 Physicians Postgraduate Press, Inc.
Purchase This PDF for $40.00
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
Receive immediate full-text access to JCP. You can subscribe to JCP online-only ($86) or print + online ($156 individual).
With your subscription, receive a free PDF collection of the NCDEU Festschrift articles. Hurry! This offer ends December 31, 2011.
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
Click here to login.
Did you forget your password?
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
Because this piece does not have an abstract, we have provided for your benefit the first 3 sentences of the full text.
There have been several case reports and open trials reporting the efficacy of opioids as treatment for depression. These have included the µ-opioid receptor full agonists oxycodone, oxymorphone, and human β-endorphin peptide as well as the µ-opioid receptor partial agonist buprenorphine. Despite this reported efficacy, these agents are generally considered to be treatments of last resort in psychiatric disorders given the risk of iatrogenic opioid dependence, to which this patient population may be particularly susceptible.